Kennedy Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $544K | Buy |
1,668
+127
| +8% | +$41.4K | 0.01% | 542 |
|
|
2025
Q1 | $416K | Buy |
1,541
+6
| +0.4% | +$1.62K | 0.01% | 591 |
|
|
2024
Q4 | $361K | Sell |
1,535
-944
| -38% | -$222K | 0.01% | 645 |
|
|
2024
Q3 | $682K | Buy |
2,479
+301
| +14% | +$82.8K | 0.02% | 624 |
|
|
2024
Q2 | $529K | Buy |
2,178
+630
| +41% | +$153K | 0.01% | 637 |
|
|
2024
Q1 | $231K | Buy |
+1,548
| New | +$231K | ﹤0.01% | 694 |
|
|
2021
Q2 | – | Sell |
-1,442
| Closed | -$204K | – | 627 |
|
|
2021
Q1 | $204K | Buy |
+1,442
| New | +$204K | ﹤0.01% | 647 |
|